“A Review on FDA Approval of Lymphoma Drug Ukoniq (Umbralisib) And Its Withdrwal Due to Safety Concerns ”. (2022) 2022. Journal of Pharmaceutical Negative Results 13 (4): 1465-74. https://doi.org/10.47750/pnr.2022.13.04.206.